Lupin launches Desvenlafaxine Extended-Release Tablets in the United States

Global pharma major Lupin Limited (Lupin) today announced the launch of Desvenlafaxine Extended-Release Tablets, 25 mg, having received an approval from the United States Food and Drug Administration (FDA).

Desvenlafaxine Extended-Release Tablets, 25 mg is a generic equivalent of Pristiq® Extended-Release Tablets, 25 mg of PF PRISM C.V.

Desvenlafaxine Extended-Release Tablets, 25 mg (RLD Pristiq®) had estimated annual sales of USD 14 million in the U.S. (IQVIA MAT June 2022).

Shares of Lupin Limited was last trading in BSE at Rs. 665.00 as compared to the previous close of Rs. 677.65. The total number of shares traded during the day was 88662 in over 4779 trades.

The stock hit an intraday high of Rs. 680.35 and intraday low of 662.05. The net turnover during the day was Rs. 59339262.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 Desvenlafaxine ExtendedReleaseTablets USFDA Approval